Yazar "Aygen, Bilgehan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report
    (Aves, 2018) Aygen, Bilgehan; Demir, Ahmet Muzaffer; Gumus, Mahmut; Karabay, Oguz; Kaymakoglu, Sabahattin; Koksal, Aydin Seref; Koksal, Iftihar
    This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
  • Küçük Resim Yok
    Öğe
    Management of Fulminant Hepatitis B: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases
    (Aves, 2013) Aydin, Mehtap; Aygen, Bilgehan; Mistik, Resit; Oncul, Oral; Tuna, Nazan; Tuncer-Ertem, Gunay; Yildiz, Orhan
    Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases set up a task force to develop a consensus report focused on fulminant hepatitis B, the only infection for which an effective antiviral approach is available. Both antiviral and non-antiviral therapies were reviewed in the report. Some practical recommendations from relevant guidelines of three international associations (i.e., European Association for the Study of the Liver, American Association for the Study of Liver Disease, and Asian Pacific Association for the Study of the Liver) were adopted, and listed with the level of evidence and the grade of recommendation at the end of the report.